PRFX logo

PRF Technologies Ltd.

PRFX
Healthcare|Drug Manufacturers - Specialty & Generic|IL
$0.87
+0.11 (+14.77%)
DCF Value
$6.39
Tangible Book / Share
$7.51
Cash / Share
$9.27

About

PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.

Stock Price

-83.9%(1Y)
1M
+1.4%
3M
-16.3%
6M
-55.1%
YTD
-72.9%
1Y
-81.4%
3Y
-98.7%
5Y
-99.9%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$70.1K
Employees6
CEOEfraim Cohen-Arazi
IPO DateSep 1, 2020
Beta1.13
52-Week Range$0.641 – $7.95
Avg Volume276,224
ExchangeNASDAQ

Ownership

Float95.4%
Shares Outstanding0.1M

Recent Insider Trades

Aviel SigalOTHER
Mar 18, 202643 shares @ $288.00
Aviel SigalOTHER
Mar 18, 2026104 shares @ $684.00
Aviel SigalOTHER
Mar 18, 2026612 shares @ $30.00
Aviel SigalOTHER
Mar 18, 20263,000 shares @ $15.75
BARON ELLEN SOTHER
Mar 18, 202650 shares @ $5400.00

Peers

ATXIAvenue Therapeutics, Inc.
$1.4M
DRMADermata Therapeutics, Inc.
$3.8M
ELABPMGC Holdings Inc.
$1.3M
NCELNewcelX Ltd.
$1.2M
NKGNNKGen Biotech, Inc.
$1.4M
PBMPsyence Biomedical Ltd.
$56.3K
UPCUniverse Pharmaceuticals Inc.
$878.1K
VRAXVirax Biolabs Group Limited
$1.1M
Data last updated: Nov 9, 2026, 04:29 AM